These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 31398418

  • 1. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
    Marques C, Gonçalves A, Pereira PMR, Almeida D, Martins B, Fontes-Ribeiro C, Reis F, Fernandes R.
    Life Sci; 2019 Oct 01; 234():116738. PubMed ID: 31398418
    [Abstract] [Full Text] [Related]

  • 2. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):828-33. PubMed ID: 24342619
    [Abstract] [Full Text] [Related]

  • 3. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
    Gonçalves A, Marques C, Leal E, Ribeiro CF, Reis F, Ambrósio AF, Fernandes R.
    Biochim Biophys Acta; 2014 Sep 17; 1842(9):1454-63. PubMed ID: 24769045
    [Abstract] [Full Text] [Related]

  • 4. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
    Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F, Reis F.
    Exp Diabetes Res; 2011 Sep 17; 2011():162092. PubMed ID: 22203828
    [Abstract] [Full Text] [Related]

  • 5. The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice via inhibiting the TGF-β/Smad signal pathway.
    Li L, Lian X, Wang Z, Zheng J, Liu J, Chu Y, Teng Y, Zhang Z.
    Pharmazie; 2019 Apr 01; 74(4):239-242. PubMed ID: 30940309
    [Abstract] [Full Text] [Related]

  • 6. Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
    Ren X, Liu G, Wang Y, Zhang W, Xue F, Li R, Yu W.
    Pharmacology; 2017 Apr 01; 100(1-2):1-13. PubMed ID: 28329747
    [Abstract] [Full Text] [Related]

  • 7. Effect of concomitant administration of coenzyme Q10 with sitagliptin on experimentally induced diabetic nephropathy in rats.
    Maheshwari R, Balaraman R, Sen AK, Shukla D, Seth A.
    Ren Fail; 2017 Nov 01; 39(1):130-139. PubMed ID: 27841100
    [Abstract] [Full Text] [Related]

  • 8. Effect of sitagliptin on tubulointerstitial Wnt/β-catenin signalling in diabetic nephropathy.
    Ren X, Zhu R, Liu G, Xue F, Wang Y, Xu J, Zhang W, Yu W, Li R.
    Nephrology (Carlton); 2019 Nov 01; 24(11):1189-1197. PubMed ID: 31412145
    [Abstract] [Full Text] [Related]

  • 9. Modulating impacts of quercetin/sitagliptin combination on streptozotocin-induced diabetes mellitus in rats.
    Eitah HE, Maklad YA, Abdelkader NF, Gamal El Din AA, Badawi MA, Kenawy SA.
    Toxicol Appl Pharmacol; 2019 Feb 15; 365():30-40. PubMed ID: 30576699
    [Abstract] [Full Text] [Related]

  • 10. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
    Liu YS, Huang ZW, Wang L, Liu XX, Wang YM, Zhang Y, Zhang M.
    J Pharmacol Sci; 2015 Mar 15; 127(3):260-74. PubMed ID: 25837922
    [Abstract] [Full Text] [Related]

  • 11. Effect of siglidine on glucose lipid metabolism and the expression of iNOS and GLP-1 receptors in diabetic rats.
    Zhang HY, Li Y, Zhong YH, Ruan LB, Yang TR, Yin HP.
    Eur Rev Med Pharmacol Sci; 2018 Dec 15; 22(24):8984-8989. PubMed ID: 30575943
    [Abstract] [Full Text] [Related]

  • 12. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
    Gault VA, Lennox R, Flatt PR.
    Diabetes Obes Metab; 2015 Apr 15; 17(4):403-13. PubMed ID: 25580570
    [Abstract] [Full Text] [Related]

  • 13. Critical role of renal dipeptidyl peptidase-4 in ameliorating kidney injury induced by saxagliptin in Dahl salt-sensitive hypertensive rats.
    Sakai M, Uchii M, Myojo K, Kitayama T, Kunori S.
    Eur J Pharmacol; 2015 Aug 15; 761():109-15. PubMed ID: 25936515
    [Abstract] [Full Text] [Related]

  • 14. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
    Karabulut S, Coskun ZM, Bolkent S.
    Pharmacol Rep; 2015 Oct 15; 67(5):846-53. PubMed ID: 26398375
    [Abstract] [Full Text] [Related]

  • 15. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
    Glorie L, Behets GJ, Baerts L, De Meester I, D'Haese PC, Verhulst A.
    Am J Physiol Endocrinol Metab; 2014 Sep 01; 307(5):E447-55. PubMed ID: 25053403
    [Abstract] [Full Text] [Related]

  • 16. CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats treated with sitagliptin.
    Coskun ZM, Koyuturk M, Karabulut S, Bolkent S.
    Pharmacol Rep; 2017 Aug 01; 69(4):822-829. PubMed ID: 28599244
    [Abstract] [Full Text] [Related]

  • 17. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Li B, Luo YR, Zhang Q, Fu SH, Chen YD, Tian JW, Guo Y.
    Vascul Pharmacol; 2021 Oct 01; 140():106854. PubMed ID: 33781961
    [Abstract] [Full Text] [Related]

  • 18. Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway.
    Al-Qabbaa SM, Qaboli SI, Alshammari TK, Alamin MA, Alrajeh HM, Almuthnabi LA, Alotaibi RR, Alonazi AS, Bin Dayel AF, Alrasheed NM, Alrasheed NM.
    Int J Mol Sci; 2023 Mar 31; 24(7):. PubMed ID: 37047505
    [Abstract] [Full Text] [Related]

  • 19. Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy.
    Jo CH, Kim S, Park JS, Kim GH.
    Kidney Blood Press Res; 2018 Mar 31; 43(3):987-999. PubMed ID: 29913457
    [Abstract] [Full Text] [Related]

  • 20. Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.
    Al-Rasheed NM, Al-Rasheed NM, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mahmoud AM.
    Drug Des Devel Ther; 2016 Mar 31; 10():2095-107. PubMed ID: 27418808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.